Omectatug clinical trials
How each study uses omectatug is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- ASKB589
- 1
Studies by the year they started
3 studies that test it; most in 2021 (1)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2023 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
AskGene Pharma, Inc. (2) · Jiangsu Aosaikang Pharmaceutical Co., Ltd. (1)
Often tested with
Tested in the same studies.
CAPOX Regimen (1) · Sintilimab (1) · Tislelizumab (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test omectatug, phase 3 first.
- Dec 2026ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ AdenocarcinomaPhase 3 · AskGene Pharma, Inc.
Studies
Open first, then newest update. How each study uses omectatug is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ AdenocarcinomaActive, not recruitingPhase 3AskGene Pharma, Inc.NCT06206733Written as ASKB589
- A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid TumorsActive, not recruitingPhase 1/2Jiangsu Aosaikang Pharmaceutical Co., Ltd.NCT04632108Written as ASKB589 Injection
- ASKB589 in Combination With CAPOX and PD-1 Inhibitors in Patients With Advanced, and Unresectable G/GEJ Cancer.Active, not recruitingPhase 1/2AskGene Pharma, Inc.NCT05632939Written as ASKB589 +CAPOX+Sintilimab/Tislelizumab
Codes
What other systems call omectatug · ClinicalTrials.gg INT017730
- UNII (FDA) QZ3WR2DNM3OMECTATUGOne source FDA
- NCI Thesaurus C179328OmectatugOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | QZ3WR2DNM3 | OMECTATUG | One source FDA |
| NCI Thesaurus | C179328 | Omectatug | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.